TY - JOUR T1 - The retrospective observational study of clinical outcomes of single dose infusion of warm blood cardioplegia in patients undergoing cardiac surgery JF - medRxiv DO - 10.1101/2021.07.15.21260424 SP - 2021.07.15.21260424 AU - Igor I. Chernov AU - Iliya A. Ivashchenko AU - Irina A. Mandel Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260424.abstract N2 - Objective The aim of the study was to assess the safety and efficacy of a normothermic cardioplegia solution N™ use and obtain additional information about dosing regimens during normothermic or mild hypothermic cardiac surgery.Methods A retrospective observational study included 150 cardio surgery patients. The primary endpoint was the intraoperative acute heart failure development. The secondary endpoints were the postoperative Troponin T concentrations, the need for catecholamine support, and the repeated infusion of a cardioplegia solution.Results The duration of aortic cross-clamping varied from 17 to 154 minutes, median 59 [interquartile range, 46 - 73] minutes. Spontaneous sinus rhythm recovery was observed in 136 (90.7%) patients. Intraoperative acute heart failure was observed in 1 case. The Troponin T concentrations were 0.331±0.143 ng/mL after surgery. Mortality was 2% (3 patients). Eight patients received an additional volume of N™ solution to maintain asystole. Among 16 patients with a cross-clamp duration greater than 90 minutes epinephrine was used in 3 (18.8%) patients in dose of more than 0.05 mcg/kg/min. Among 134 patients cross-clamp duration less than 90 minutes the catecholamine support was used in 4 (3%) patients, p=0.027.Conclusions A primary single-dose infusion of cardioplegia solution N™ provides myocardial protection for 59 [interquartile range, 46 - 73] minutes and up to 154 minutes. The catecholamine support in the group of aortic cross-clamp duration less than 90 minutes was used lesser than in the group of aortic cross-clamp duration greater than 90 minutes (3% and 18.8%, respectively). The cardioprotection during cardiopulmonary bypass surgery especially in elderly patients with concomitant disease needs to be confirmed in a future investigations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The Ethical Committee of the Federal Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation waived the need for written informed consent to perform this retrospective analysis. The study was approved by the Ethical Committee of the Federal Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are available from the corresponding author on reasonable request.AHFAcute heart failureBMIbody mass indexCPBcardiopulmonary bypassICUintensive cure unitLVEFleft ventricle ejection fraction ER -